Peripheral blood mononuclear cells (PBMC) were prepared and cultured (14, 15) to 24 establish the numbers of ex vivo IFN-γ secreting cells (spot forming cells, SFC) in 25 ELISPOT assays (14) after in vitro stimulation with recombinant rAg85A (5 µg/ml, 26 Lionex, Braunschweig, Germany), or bovine tuberculin PPD (10 µg/ml, Veterinary 27
Laboratories Agency-Weybridge). The results, shown in Figure 1A demonstrated that all 28 vaccination protocols resulted in the induction of T cells specific for Ag85A. Priming 29 vaccination with rAd85A resulted in rAg85A specific responses peaking at weeks 1 to 3 30 in the rAd85-rAd85A and rAd85A-BCG groups (254+131 and 155+50 SFC/10 6 PBMC, 31 respectively). Similar response levels against rAg85A were observed after BCG priming 32 in the BCG-rAd85A group. Although BCG-induced IFN-γ response peaks may vary 33 between experiments, the responses of these BCG vaccinated calves were not 34 significantly different from results of earlier BCG vaccination experiments (16). In 35 addition, the response kinetic was identical to previous results obtained after a single 36 BCG vaccination which resulted in peak responses between weeks 3 and 5 followed by a 37 decline in responses towards pre-vaccination levels between weeks 6 -8 post-vaccination 38 (16). Thus, the responses described up to week 6, i.e. immediately before boosting in the 39 BCG prime group, are identical to those observed previously following a single BCG 40 vaccination ('BCG alone' group) and were expected to further decline after week 6 if the 41 cattle were not boosted. 42
43
Boosting BCG primed calves with rAd85A resulted in statistically significant anamnestic 44 IFN-γ responses compared to pre-boost peak levels (Fig. 1A , 5/5 calves, mean responses , 45 pre-boost 'BCG alone' peak values, week 4: 206+67 SFC/10 6 PBMC; post -boost: 914 + 46 255 SFC/10 6 PBMC, p=0.028). This enhanced ex vivo response peaked one week post-47 rAd85A infection (week 7), and was significantly different from the other two groups at 48 this time point (p = 0.011, compared to post-boost peak responses at week 7 in 49 rAd85A/BCG, and week 4 in rAd85A-rAd85A). Ex vivo responses contracted over the 50 following weeks (Fig. 1A) . Boosting the animals in the rAd85A-rAd85A group with 51 rAd85A at week 3 resulted in enhanced responses compared to pre-boost peak levels in 52 2/5 animals (mean SFC: 212+111 SFC/10 6 PBMC, Fig. 1A ), peaking one week after the 53 boost. Boosting rAd85A primed cattle with BCG resulted in enhanced rAg85A responses 54 in 3/5 animals compared to levels at the time of boosting at week 6 (100 + 39 SFC/10 6 at 55 week 6, 127 + 80 SFC/10 6 PBMC, Fig. 1A ), and never exceeded IFN-γ levels observed 56 after rAd85A priming. Responses after ex vivo stimulation with bovine PPD were also 57 determined and confirmed the results obtained with rAg85A (not shown). One 58 mechanism for the failure of BCG to recall rAd85A-primed responses, or even to induce 59 stronger responses on its own, could be due to Ad85A-induced pre-existing immunity to 60 BCG. A similar mechanism has been postulated to explain why exposure to 61 environmental mycobacteria results in immunity to cross reacting antigens that limits 62 BCG multiplication and protective immunity (1). It is also possible that rAd85A is a 63 weak immunogen in cows, poor at priming immune responses but capable of boosting 64 existing responses.. 6 PBMC/ml with rAg85 protein (2 77 µg/ml). Recombinant human IL-2 (to 10 U/ml, Sigma Poole, GB) was added to the 78 cultures on days 5 and 8). On days 10 and 12, half of the supernatant was replaced with 79 IL-2-free medium. On day 13, 2x10 4 cells/well were added to ELISPOT plates, and 80 incubated together with rAg85A (5mg/ml) or a Ag85A peptide cocktail (peptides 81 1, 3,4,6,8,11,16,17,18,19,21,22,23 see: (16) ; 6 mg/ml each peptide). Large numbers of 82 memory cells were found after vaccination with all three protocols (Fig. 1B) . However, 83 rAd85A-rAd85A vaccination resulted in the weakest cultured ELISPOT responses 84 (rAg85A stimulation: 10,650+1,270 SFC/10 6 cells) compared to BCG-rAd85A and 85 rAd85A-BCG (22, 720+2, 780, 19, 380+3, 430SFC/10 6 cells, respectively), although only 86 the responses in the BCG-rAd85A group were statistically significantly larger than those 87 of the rAd85A-rAd85A vaccinated calves (p < 0.05, Fig. 1B ). While the cultured 88 ELISPOT responses observed in the BCG-rAd85A vaccinated calves were predictably 89 the strongest, rAd85A-BCG vaccination also resulted in re-call responses comparable to 90 BCG-rAd85A vaccination (Fig. 1B) was boosted by intranasal rAd85A vaccination, peaking two weeks post-boost ( Fig.2A,  106 week 9). Enhanced Ag85A-specific central memory responses were also demonstrable 107 by cultured ELISPOT after intranasal boosting with rAd85A (Fig. 2B) 
